The drug fezolinetant, a selective neurokinin-3 receptor antagonist under investigation for treatment of menopausal vasomotor symptoms, showed acceptable long-term safety and tolerability during a 1-year phase 3 randomized controlled trial, according to data presented at the annual meeting of the North American Menopause Society. The study, called SKYLIGHT 4, examined...
Nonhormonal Drug Fezolinetant Found Safe for Hot Flashes in Yearlong Study
Conference Report | 19 October 2022
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.Create a Free Account I have an account